Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Ikonisys

Ikonisys?uq=3Oe4kK1Z
1999 FOUNDED
PRIVATE STATUS
51-60 EMPLOYEES
Later Stage VC LATEST DEAL TYPE
$1.44M LATEST DEAL AMOUNT
14 INVESTORS
Description

Developer of diagnostic tests designed to transform diagnostic medicine through early, accurate and non-invasive disease detection. The company's diagnostic tests detect a single cell and identify its molecular signals, enabling large and regional reference labs, hospitals, research institutions and practice groups to reduce the risk of human error, lower costs, and expand test volume capacity.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Other Devices and Supplies
Primary Office
  • 5 Science Park
  • New Haven, CT 06511
  • United States

+1 (203) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Ikonisys’s full profile, request a free trial.

Ikonisys Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 20-Jul-2012 $1.44M 000.00 Completed Generating Revenue
7. Later Stage VC 03-Aug-2010 00.00 0000 Completed Generating Revenue
6. Grant 31-Dec-2009 00000 000.00 Completed Generating Revenue
5. Later Stage VC (Series E) 17-Oct-2007 0000 000.00 000.00 Completed Generating Revenue
4. Later Stage VC (Series D) 08-Mar-2006 0000 000.00 0000 Completed Generating Revenue
3. Later Stage VC (Series C) 11-Dec-2003 00.000 00.000 000.00 Completed Startup
2. Early Stage VC (Series B) Completed Startup
1. Early Stage VC (Series A) Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Ikonisys Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series E 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series D 00,000,000 00.000000 00 00 00 00 00.000
Series C 0,000,000 00.000000 00 00 00 00 0.000
Series B2 000,000 00.000000 00 00 00 00 0.000
Series B1 000,000 00.000000 00 00 00 00 0.000
Series B 125,000 $0.010000 $4 $4 1x $4 0.18%
Series A 1,100,000 $0.010000 $1.81 $1.81 1x $1.81 1.61%
To view this company’s complete Cap Table, request access »

Ikonisys Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Qualifying Therapeutic Discovery Project Government Minority 000 0000 000000 0
Everfin Corporation Minority 000 0000 000000 0
Goldman Sachs Merchant Banking Division Merchant Banking Firm Minority 000 0000 000000 0
Investors Group Other Minority 000 0000 000000 0
Palisade Capital Management Asset Manager Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Ikonisys Executive Team (14)

Name Title Board
Seat
Contact
Info
Carlo Medici Chief Executive Officer
Triantafyllos Tafas Ph.D President, Co-founder & Board Member
Mary Mansfield Controller
Eric Kershnar Director, Business Development
Maribeth Stewart Director of Operations, Clinical Laboratory, Quality Assurance and Regulatory Compliance

7 Former Executives

You’re viewing 5 of 14 executives. Get the full list »

Ikonisys Board Members (12)

Name Representing Role Since Contact
Info
Christopher Dawe Self Board Member 000 0000
Fulvio Bracco Self Board Member 000 0000
Marco Prete Self Board Member 000 0000
Mario Mauri Self Board Member 000 0000
Pramod Srivastava Ikonisys Co-Founder, Board Member & Senior Advisor to the Board 000 0000

2 Former Board Members

You’re viewing 5 of 12 board members. Get the full list »